Ubs Group Ag Regenxbio Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Regenxbio Inc. stock. As of the latest transaction made, Ubs Group Ag holds 103,130 shares of RGNX stock, worth $964,265. This represents 0.0% of its overall portfolio holdings.

Number of Shares

103,130

Previous 141,420 27.08%

Holding current value

$964,265

Previous $2.98 Million 59.52%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$11.51 - $21.53 $440,717 - $824,383	-38,290 Reduced 27.08%	103,130 $1.21 Million
Q1 2024 May 13, 2024	SELL	$12.17 - $24.61 $82,865 - $167,569	-6,809 Reduced 4.59%	141,420 $2.98 Million
Q4 2023 Feb 09, 2024	BUY	$12.89 - $20.82 $1.05 Million - $1.69 Million	81,231 Added 121.24%	148,229 $2.66 Million
Q3 2023 Nov 09, 2023	BUY	$16.46 - $19.99 $75,683 - $91,914	4,598 Added 7.37%	66,998 $1.1 Million
Q2 2023 Aug 11, 2023	SELL	$17.23 - $21.71 $123,728 - $155,899	-7,181 Reduced 10.32%	62,400 $1.25 Million
Q1 2023 May 12, 2023	SELL	$18.08 - $24.55 $780,766 - $1.06 Million	-43,184 Reduced 38.3%	69,581 $1.32 Million
Q4 2022 Feb 08, 2023	BUY	$20.4 - $24.73 $1.51 Million - $1.83 Million	74,192 Added 192.34%	112,765 $2.56 Million
Q3 2022 Nov 10, 2022	SELL	$22.29 - $35.04 $264,181 - $415,294	-11,852 Reduced 23.5%	38,573 $1.02 Million
Q2 2022 Aug 10, 2022	SELL	$19.35 - $35.04 $104,373 - $189,005	-5,394 Reduced 9.66%	50,425 $1.25 Million
Q1 2022 May 16, 2022	SELL	$24.62 - $34.31 $10.2 Million - $14.2 Million	-413,672 Reduced 88.11%	55,819 $1.85 Million
Q4 2021 Feb 14, 2022	SELL	$30.19 - $40.28 $2.1 Million - $2.8 Million	-69,530 Reduced 12.9%	469,491 $15.4 Million
Q3 2021 Nov 15, 2021	BUY	$29.09 - $45.68 $420,408 - $660,167	14,452 Added 2.76%	539,021 $22.6 Million
Q2 2021 Aug 13, 2021	BUY	$32.46 - $40.48 $1.32 Million - $1.64 Million	40,565 Added 8.38%	524,569 $20.4 Million
Q1 2021 May 12, 2021	BUY	$33.61 - $49.95 $1.35 Million - $2.01 Million	40,167 Added 9.05%	484,004 $16.5 Million
Q4 2020 Feb 11, 2021	SELL	$26.52 - $49.35 $5.8 Million - $10.8 Million	-218,575 Reduced 33.0%	443,837 $20.1 Million
Q3 2020 Nov 12, 2020	BUY	$27.01 - $40.26 $9.79 Million - $14.6 Million	362,374 Added 120.78%	662,412 $18.2 Million
Q2 2020 Jul 31, 2020	SELL	$27.75 - $43.44 $9.04 Million - $14.1 Million	-325,587 Reduced 52.04%	300,038 $11.1 Million
Q1 2020 May 01, 2020	SELL	$21.5 - $54.2 $626,746 - $1.58 Million	-29,151 Reduced 4.45%	625,625 $20.3 Million
Q4 2019 Feb 14, 2020	BUY	$34.54 - $44.87 $4.87 Million - $6.33 Million	140,979 Added 27.44%	654,776 $26.8 Million
Q3 2019 Nov 14, 2019	BUY	$31.84 - $50.88 $7.98 Million - $12.8 Million	250,703 Added 95.29%	513,797 $18.3 Million
Q2 2019 Aug 14, 2019	BUY	$42.0 - $59.29 $9 Million - $12.7 Million	214,244 Added 438.58%	263,094 $13.5 Million
Q1 2019 May 14, 2019	SELL	$40.82 - $62.45 $2.32 Million - $3.56 Million	-56,936 Reduced 53.82%	48,850 $2.8 Million
Q4 2018 Feb 14, 2019	BUY	$39.11 - $75.15 $1.16 Million - $2.23 Million	29,736 Added 39.1%	105,786 $4.44 Million
Q3 2018 Nov 14, 2018	BUY	$65.0 - $82.15 $2.62 Million - $3.31 Million	40,293 Added 112.69%	76,050 $5.74 Million
Q2 2018 Aug 14, 2018	SELL	$27.2 - $74.35 $203,836 - $557,178	-7,494 Reduced 17.33%	35,757 $2.57 Million
Q1 2018 May 15, 2018	BUY	$24.05 - $37.5 $432,755 - $674,775	17,994 Added 71.24%	43,251 $1.29 Million
Q4 2017 Feb 14, 2018	SELL	$26.0 - $34.6 $25,506 - $33,942	-981 Reduced 3.74%	25,257 $840,000
Q3 2017 Nov 14, 2017	BUY	$18.0 - $32.95 $359,388 - $657,879	19,966 Added 318.34%	26,238 $865,000
Q2 2017 Aug 14, 2017	BUY	N/A	5,222 Added 497.33%	6,272 $124,000
Q1 2017 Nov 14, 2017	BUY	N/A	1,050	1,050 $20,000

Others Institutions Holding RGNX

# of Institutions

193

Shares Held

43.5M

Call Options Held

58.9K

Put Options Held

58.4K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $404M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account